

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 27, at the end of the application.

REMARKS


Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOS:1-20, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the Specification and Abstract by the current Amendment. The attached pages are captioned **"VERSION WITH MARKINGS TO SHOW CHANGES MADE."**

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,


Kevin L. Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
KLB:dmw



PATENT

GILM and BOSS
Application No.: 09/815,023
Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 28 of page 5 has been amended as follows:

The term "insect cell membrane transporter" also refers to polymorphic variants, alleles, interspecies homologs, and mutants that: (1) have about 70% amino acid sequence identity, preferably about 80-90% amino acid sequence identity to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, or 16 over a window of about at least 50-100 amino acids; (2) binds to polyclonal antibodies raised against an immunogen comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16 and conservatively modified variants thereof; (3) specifically hybridize (with a size of at least about 500, preferably at least about 900 nucleotides) under stringent hybridization conditions to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, and 15 and conservatively modified variants thereof; or (4) are amplified by primers that specifically hybridize under stringent conditions to the same sequence as degenerate primers, including, but not limited to, the following:

1S forward primer for NTTs: (A69) (SEQ ID NO:17)

5'-CGGAATTCTGG(G/C)CAA(T/C)(G/A)TITGG(A/C)GITT(C/T)CCNTA-3'

4A reverse primer for NTTs: (A67) (SEQ ID NO:18)

5'-GCCAAGCTTGAAGAAGAT(C/T)TG(G/A)GIIGCIGC(G/A)TCNA(C/T/G)CCA-3'

2S reverse primer for NTTs: (A70) (SEQ ID NO:19)

C-TCC-ATG-GA(AG)-AA(TC)-GGI-GGI-GGI-GCN-TT

3A reverse primer for NTTs: (A68) (SEQ ID NO:20)

GILL and ROSS
Application No.: 09/815,923
Page 5

PATENT

GGC-GAG-CTC-GGC-ICC-IGG-IAG-IGT-N(AG)C-NCC

SF 1281161 v1